S-1: Aclarion, Inc. Files for Public Offering Amidst Nasdaq Compliance Challenges

Aclarion, Inc. is seeking to raise capital through a public offering of common stock and warrants, while also addressing ongoing compliance issues with Nasdaq listing requirements.

Summary

• Aclarion, Inc. has filed a registration statement for a public offering involving common stock, pre-funded warrants, and common warrants.
• The offering is structured to allow purchasers to buy pre-funded warrants instead of common stock to avoid exceeding ownership limits.
• The company is facing delisting from Nasdaq due to non-compliance with minimum bid price and stockholders' equity requirements.
• Aclarion intends to use the proceeds from the offering to redeem outstanding preferred stock, expand product platforms, and support sales and marketing efforts.
• The company's technology focuses on using Magnetic Resonance Spectroscopy (MRS) to diagnose discogenic low back pain.
• A clinical study showed that 97% of patients improved when surgically treated discs were identified as painful by Aclarion's technology.
• The company has secured Category III CPT codes for its technology, which are a first step in the reimbursement process.
• Aclarion is also participating in a $150 million NIH-funded study to evaluate data inputs for predicting optimal back pain treatment paths.
• The company's current product is compatible with certain SIEMENS MRI scanner models, limiting its market reach.
• Aclarion has a history of net losses and has expressed substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the technology shows promise and has some clinical validation, the company faces significant financial and regulatory challenges, including potential delisting from Nasdaq and a history of net losses. The need for additional funding and the uncertainty surrounding its ability to continue as a going concern also contribute to a negative sentiment.

Positives

• Aclarion's technology has shown a 97% success rate in a clinical study when surgically treated discs were identified as painful by their technology.
• The company has secured Category III CPT codes, which is a first step in the reimbursement process.
• Aclarion is participating in a $150 million NIH-funded study to evaluate data inputs for predicting optimal back pain treatment paths.
• The company has a strategic partnership with Alphatec Holdings, Inc. to co-market Nociscan in targeted markets.
• Aclarion has received initial payer coverages of Nociscan by AXA, Aviva and Vitality in London, UK.
• The company has a strong intellectual property portfolio with 22 U.S. Patents, 17 Foreign Patents, 6 pending U.S. patent applications, and 7 pending Foreign patent applications.

Negatives

• Aclarion is not in compliance with Nasdaq's minimum bid price and stockholders' equity requirements and faces potential delisting.
• The company has a history of net losses and has expressed substantial doubt about its ability to continue as a going concern.
• Aclarion's current product is only compatible with certain SIEMENS MRI scanner models, limiting its market reach.
• The company's early clinical evidence is supported by a single, relatively small clinical study at a single clinical center sponsored by the company.
• The company's commercial success depends on attaining significant market acceptance of its technology among patients, clinicians and imaging facilities.
• The company's current product is dependent on certain processes that are not optimized to support the scaling of its technology.

Risks

• The company is not currently in compliance with Nasdaq's minimum bid price and stockholders' equity rules, which could lead to delisting.
• Aclarion has a history of net losses and may not achieve or sustain profitability.
• The company's auditors have expressed substantial doubt about its ability to continue as a going concern.
• The company may need to raise additional capital, which may not be available on acceptable terms.
• The company's internal controls over financial reporting have material weaknesses.
• The company's commercial success depends on market acceptance of its technology.
• The company's current product is only compatible with certain SIEMENS MRI scanner models.
• The company may be unable to obtain, maintain, protect, enforce and defend its intellectual property.
• The company may be unable to compete successfully with other diagnostic options for low back pain.
• The company may not obtain adequate reimbursement for its technology.
• The company's collection, use, storage, disclosure, transfer and other processing of sensitive and personal information could give rise to significant costs, liabilities and other risks.
• The company's current product is supported by a single clinical study at a single clinical center involving one spine surgeon who has a financial interest in the Company.
• The company may fail to continue to meet the listing standards of The Nasdaq Capital Market whether or not this offering occurs.
• The company's current product is dependent on certain processes that are not optimized to support the scaling of its technology.

Future Outlook

The company believes its cash on hand will be sufficient to fund current operating plans into December 2024, but will need to raise additional funds to continue funding its technology development and commercialization efforts over the following twelve months. Assuming the receipt of the maximum amount of net proceeds from this offering, the company believes its cash resources would be sufficient to fund its current operating plans into the first quarter of 2025.

Management Comments

• Management has plans to secure additional funding.
• The Company intends to take all reasonable measures available to maintain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq.

Industry Context

The company is addressing the $134.5 billion U.S. low back and neck pain market, which is the most costly healthcare condition in the United States. The company's technology is aimed at improving the outcomes of surgical interventions for discogenic low back pain, which is a significant issue in the market.

Comparison to Industry Standards

• The company's technology is positioned as an alternative to the current standard of care, which includes MRI and invasive discography.
• The company's clinical study showed a 97% success rate when surgically treated discs were identified as painful by their technology, compared to a 41-57% success rate for traditional methods.
• The company's technology is designed to address the limitations of current diagnostic methods, which often fail to accurately identify the source of pain.
• The company's technology is intended to provide a non-invasive, objective, and quantifiable alternative to the subjective and invasive Provocation Discogram test.
• The company's technology is designed to be compatible with existing MRI scanners, which is a significant advantage over other diagnostic methods that require additional equipment.

Related Party Transactions

• The company has entered into a number of investment and commercial transactions with Nuvasive.
• The company has certain financial relationships with medical doctors and other healthcare providers who are investors and shareholders in the Company and/or paid consultants, clinical investigators, or speakers promoting our products and clinical results, some of whom are also our customers who pay us for patients receiving a NOCISCAN exam, or otherwise prescribe and get paid for interpreting a NOCISCAN exam.

Stakeholder Impact

• Shareholders may experience dilution due to the public offering and potential future sales of common stock.
• Employees may be affected by the company's financial instability and potential delisting from Nasdaq.
• Customers may be impacted by the company's ability to continue operations and provide its technology.
• Suppliers and creditors may be affected by the company's financial instability and potential inability to meet its obligations.

Next Steps

• The company intends to implement a reverse stock split in the near future in order to assist with the Companys compliance with Nasdaqs Bid Price Requirement.
• The company intends to take all reasonable measures available to maintain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq.
• The company intends to use the net proceeds from this offering, together with our existing cash, to redeem all outstanding shares of our Series B Preferred Stock and Series C Preferred Stock, each at a redemption price per share equal to $1,000 plus all accrued but unpaid dividends on each such share, with the remaining net proceeds to be used to build out the product platforms, expand our sales and marketing efforts, and for general and administration expenses and other general corporate purposes.

Key Dates

Keywords

Magnetic Resonance Spectroscopy, MRS, Discogenic Low Back Pain, DLBP, Spine Surgery, Intervertebral Disc, Biomarkers, NOCISCAN, CPT Codes, Nasdaq, Clinical Study, Reimbursement, Medical Device, Healthcare Technology, AI, Artificial Intelligence